Under pressure to show Moderna can grow the company’s mRNA vaccines portfolio beyond COVID-19, CEO Stéphane Bancel has talked down his rivals in the field.
Moderna’s CEO Stéphane Bancel believes his company holds the greatest advantage in mRNA-based vaccines for infectious diseases, and has talked down the challenge from Pfizer/BioNTech, and dismissed the chances of GlaxoSmithKline and Sanofi breaking into the field.
Moderna has been catapulted into the biopharma big league thanks to the global success of its COVID-19 vaccine SpikeVax, which earned the company $18
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.
